45054 Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 

Information Officer (HFA–250), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301–827–

1482. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of December 13, 2006 

(71 FR 74924), the agency announced 

that the proposed information collection 

had been submitted to OMB for review 

and clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0530. The 

approval expires on May 31, 2010. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.fda.gov/ 

ohrms/dockets. 

Dated: August 6, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–15614 Filed 8–9–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Indian Health Service 

Request for Public Comment: 60-Day 

Proposed Information Collection: 

Application for Participation in the IHS 

Scholarship Program 

AGENCY: Indian Health Service, HHS. 

ACTION: Notice. 

SUMMARY: In compliance with section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 which requires 

60 days for public comment on 

proposed information collection 

projects, the Indian Health Service (IHS) 

is publishing for comment a summary of 

a proposed information collection to be 

submitted to the Office of Management 

and Budget (OMB) for review. 

Proposed Collection: Title: 0917–

0006, ‘‘Application for Participation in 

the IHS Scholarship Program.’’ Type of 

Information Collection Request: Threeyear extension, without change of 

currently approved information 

collection, 0917–0006, ‘‘Application for 

Participation in the IHS Scholarship 

Program.’’ Form Number(s): IHS–856, 

856–2 through 856–8, IHS–815, IHS–

816, IHS–817, IHS–818, D–02, F–02, F–

04, G–02, G–04, H–07, H–08, J–04, J–05, 

K–03, K–04, and L–03. Reporting 

formats are contained in an IHS 

Scholarship Program application 

booklet. Need and Use of Information 

Collection: The IHS Scholarship Branch 

needs this information for program 

administration and uses the information 

to solicit, process, and award IHS Pregraduate, Preparatory, and/or Health 

Professions Scholarship grants and 

monitor the academic performance of 

awardees and to place awardees at 

payback sites. The IHS Scholarship 

Program is streamlining the application 

to reduce the time needed by applicants 

to complete and provide the 

information. The IHS Scholarship 

Program plans on using information 

technology to make the application 

electronically available on the internet. 

Affected Public: Individuals, not-forprofit institutions and State, local or 

tribal government. Type of Respondents: 

Students pursuing health care 

professions. 

The table below provides: Types of 

data collection instruments, Estimated 

number of respondents, Number of 

responses per respondent, Annual 

number of responses, Average burden 

hour per response, and Total annual 

burden hour(s). 

Data collection instruments(s) Number of 

respondents 

Responses 

per respondent 

Total annual 

response 

Burden hour 

per response * 

Annual 

burden hours 

Scholarship Application (IHS–856) .............................. 1500 1 1500 1.00 (60 min) 1500 

Checklist (856–2) ......................................................... 1500 1 1500 0.13 (8 min) 195 

Course Verification (856–3) ......................................... 1500 1 1500 0.70 (42 min) 1050 

Faculty/Employer Application (856–4) ......................... 1500 2 3000 0.83 (50 min) 2490 

Justification (856–5) ..................................................... 1500 1 1500 0.75 (45 min) 1125 

Federal Debt (856–6) ................................................... 1500 1 1500 0.13 (8 min) 195 

Job Experience (856–7) ............................................... 25 1 25 0.83 (50 min) 21 

Accept/Decline (856–8) ................................................ 650 1 650 0.13 (8 min) 84 

Receipt of Application (815) ........................................ 1500 1 1500 0.03 (2 min) 45 

Address Change Notice (816) ..................................... 25 1 25 0.02 (1 min) 25 

Scholarship Program Agreement (817) ....................... 850 1 850 0.05 (3 min) 43 

Health Professions Contract (818) .............................. 650 1 650 0.05 (3 min) 33 

Stipend Check (D–02) ................................................. 100 1 100 0.13 (8 min) 13 

Enrollment (F–02) ........................................................ 1300 1 1300 0.13 (8 min) 169 

Academic Problem/Change (F–04) ............................. 50 1 50 0.13 (8 min) 6 

Request Assistance (G–02) ......................................... 217 1 217 0.13 (8 min) 28 

Summer School (G–04) ............................................... 193 1 193 0.10 (6 min) 19 

Placement (H–07) ........................................................ 250 1 250 0.18 (11 min) 45 

Graduation (H–08) ....................................................... 250 1 250 0.17 (10 min) 43 

Site Preference (J–04) ................................................. 150 1 150 0.13 (8 min) 20 

Travel Reimb (J–05) .................................................... 150 1 150 0.10 (6 min) 15 

Status Report (K–03) ................................................... 250 1 250 0.25 (15 min) 63 

Preferred Assignment (K–04) ...................................... 200 1 200 0.75 (45 min) 150 

Request of Deferment (L–03) ...................................... 20 1 20 0.13 (8 min) 3 

Total ...................................................................... 15,830 ............................ ........................ ............................ 7,380 

* For ease of understanding, burden hours are also provided in actual minutes. 

There are no Capital Costs, Operating 

Costs, and/or Maintenance Costs to 

report. 

Request for Comments: Your written 

comments and/or suggestions are 

invited on one or more of the following 

points: (a) Whether the information 

collection activity is necessary to carry 

out an agency function; (b) whether the 

agency processes the information 

collected in a useful and timely fashion; 

(c) the accuracy of public burden 

estimate (the estimated amount of time 

needed for individual respondents to 

provide the requested information); (d) 


sroberts on PROD1PC70 with PROPOSALS
Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 45055 

whether the methodology and 

assumptions used to determine the 

estimates are logical; (e) ways to 

enhance the quality, utility, and clarity 

of the information being collected; and 

(f) ways to minimize the public burden 

through the use of automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Send Comments and Requests for 

Further Information: Send your written 

comments, requests for more 

information on the proposed collection, 

or requests to obtain a copy of the data 

collection instrument(s) and 

instructions to: Mrs. Chris Rouleau, IHS 

Reports Clearance Officer, 801 

Thompson Ave., Suite 450, Rockville, 

MD 20852–1601; call non-toll free (301) 

443–5938; send via facsimile to (301) 

443–2316; or send your e-mail requests, 

comments, and return address to: 

Christina.Rouleau@ihs.gov. 

Comment Due Date: Your comments 

regarding this information collection are 

best assured of having full effect if 

received within 60 days of the date of 

this publication. 

Dated: August 3, 2007. 

Charles W. Grim, 

Assistant Surgeon General, Director, Indian 

Health Service. 

[FR Doc. 07–3895 Filed 8–9–07; 8:45 am] 

BILLING CODE 4165–16–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Treatment for Cystic Fibrosis Cells and 

Other Reduced ClØConductance Cells 

Description of Technology: Cystic 

fibrosis is the most common fatal 

genetic disease among Caucasians. It is 

caused by a defect in the cystic fibrosis 

transmembrane regulator (CFTR) 

protein. A normal CFTR transports 

chloride ions across the membrane of 

epithelial cells lining several organs in 

the body such as the lungs and the 

pancreas. The most debilitating 

consequence of the defective CFTR 

protein occurs in the lungs of cystic 

fibrosis patients, where insufficient 

chloride transport prevents water from 

exiting epithelial cells. This causes the 

lungs to produce abnormally thick, 

sticky mucus that clogs the airways and 

leads to fatal lung infections. Currently 

there is no cure for the disease. Present 

treatments result in undesired side 

effects such as cardiac, renal, and/or 

central nervous system tissue. 

The NIH has developed a method of 

identifying cystic fibrosis 

transmembrane regulator binding 

compounds for treating cells having a 

reduced Cl¥conductance, such as 

cystic fibrosis cells. It has also identified 

a compound, 1,3-Diallyl-8- 

cyclohexylxanthine (DAX), for potential 

treatment of cystic fibrosis. Because 

DAX has specificity in target areas of 

activity, treatment with this compound 

can potentially prevent all of the 

complications of cystic fibrosis 

including the production of abnormal 

mucus and without undesired side 

effects. DAX is active in extremely low 

concentrations. 

Applications: Diagnostic; Therapeutic 

agent for the treatment of cells having a 

reduced Cl¥conductance. 

Market: This is intended for cystic 

fibrosis or other reduced 

Cl¥conductance cells; Approximately 

70,000 children and young adults 

worldwide, including 30,000 in the U.S. 

and 30,000 in Europe. 

Development Status: Dr. Pollard has 

performed pre-clinical testing. 

Inventors: Dr. Harvey B. Pollard and 

Dr. Kenneth A. Jacobson (NIDDK). 

Publications: 

1. N Arispe et al. ‘‘Direct activation of 

cystic fibrosis transmembrane 

conductance regulator channels by 8–

cyclopentyl–1,3–dipropylxanthine 

(CPX) and 1,3–diallyl–8–

cyclohexylxanthine (DAX),’’ J Biol 

Chem. 1998 Mar 6;273(10):5727–5734. 

2. KA Jacobson, C Guay-Broder, PJM 

van Galen, C Gallo-Rodriguez, N 

Melman, O Eidelman, HB Pollard. 

‘‘Stimulation by alkylxanthines of 

chloride efflux in CFPAC-cells does not 

involve A1-adenosine receptors,’’

Biochemistry, 1995 Jul 18;34(28):9088–

9094. 

Patent Status: 

U.S. Patent No. 5,877,179 issued 02 

Mar 1999 (HHS Reference No. E–138–

1992/1–US–01). This patent is for 

identifying binding compounds and 

composition of matter. 

U.S. Patent No. 6,083,954 issued 04 

Jul 2000 (HHS Reference No. E–138–

1992/1–US–02). This patent is for 

treating CF. 

Foreign patent rights available. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Catherine A. 

Wendelken; 301/435–5282; 

wendelkenc@od.nih.gov. 

Dated: August 3, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–15622 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Research Program Project on Hypertension in 

Youth. 

Date: September 7, 2007. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Washington, 1515 

Rhode Island Ave., NW., Washington, DC 

20005. 

Contact Person: Holly Patton, PhD, 

Scientific Review Administrator, Review 


sroberts on PROD1PC70 with PROPOSALS